Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747).

@article{Bourdonnec2009SpirocyclicDO,
  title={Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747).},
  author={Bertrand Le Bourdonnec and Rolf T. Windh and Lara K Leister and Q Jean Zhou and Christopher W Ajello and Minghua Gu and Guo-Hua Chu and Paul A Tuthill and William M Barker and Michael Koblish and Daniel D Wiant and Thomas M. Graczyk and Serge Belanger and Joel A Cassel and Marina S Feschenko and Bernice L Brogdon and Steven A Smith and Michael J. Derelanko and Steve Kutz and Patrick J. Little and Robert N Dehaven and Diane L Dehaven-Hudkins and Roland E. Dolle},
  journal={Journal of medicinal chemistry},
  year={2009},
  volume={52 18},
  pages={5685-702}
}
Selective, nonpeptidic delta opioid receptor agonists have been the subject of great interest as potential novel analgesic agents. The discoveries of BW373U86 (1) and SNC80 (2) contributed to the rapid expansion of research in this field. However, poor drug-like properties and low therapeutic indices have prevented clinical evaluation of these agents. Doses… CONTINUE READING